Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic CholangiocarcinomaLipika Goyal, John Bridgewater, Tehseen Salimi et al.|New England Journal of Medicine|2023Cited by 530
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trialSalvatore Siena, Takayuki Yoshino, Maria Di Bartolomeo et al.|The Lancet Oncology|2021Cited by 411
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studiesYoshiaki Nakamura, Takayuki Yoshino, Hiroya Taniguchi et al.|Nature Medicine|2020Cited by 366
Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With <i>RAS</i> Wild-type, Left-Sided Metastatic Colorectal CancerJun Watanabe, Takayuki Yoshino, Kei Muro et al.|JAMA|2023Cited by 255
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trialKanwal Raghav, Takayuki Yoshino, Salvatore Siena et al.|The Lancet Oncology|2024Cited by 124